4.5 Article

Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy

Journal

BREAST CANCER RESEARCH AND TREATMENT
Volume 181, Issue 2, Pages 347-359

Publisher

SPRINGER
DOI: 10.1007/s10549-020-05622-5

Keywords

Sexual problems; Breast cancer; Endocrine treatment; Treatment-induced symptoms; Depression

Categories

Funding

  1. International Breast Cancer Study Group
  2. US National Cancer Institute
  3. Breast Cancer Research Foundation [16-185, 17-187, 18-003]
  4. Ipsen
  5. Pfizer
  6. IBCSG: Frontier Science and Technology Research Foundation
  7. Swiss Group for Clinical Cancer Research (SAKK)
  8. Cancer Research Switzerland
  9. Oncosuisse
  10. Cancer League Switzerland
  11. Foundation for Clinical Cancer Research of Eastern Switzerland (OSKK)
  12. Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU) on behalf of the National Cancer Research Institute Breast Clinical Studies Group United Kingdom (NCRI-BCSG-ICR-CTSU Partnership) [Cancer Research UK] [A15955, CRUKE/03/022, CRUKE/03/023]
  13. National Institute for Health Research Royal Marsden/Institute of Cancer Research Biomedical Research Centre
  14. Alliance for Clinical Trials in Oncology [US NIH U10CA180821]
  15. SWOG [US NIH CA32102]
  16. ECOG-ACRIN Cancer Research Group [US NIH CA21115, CA16116]
  17. NRG Oncology [US NIH] [U10CA180868, U10CA180822, UG1CA189867]
  18. Breast Cancer Trials Australia New Zealand [NHMRC 351161, 510788, 1105058]
  19. TerSera
  20. National Institute for Health Research/Cambridge Biomedical Research Centre
  21. Canadian Cancer Trials Group [US NIH CA077202]
  22. Canadian Cancer Trials Group [Canadian Cancer Society Research Institute] [015469, 021039]

Ask authors/readers for more resources

Purpose Sexual dysfunction is an important concern of premenopausal women with early breast cancer. We investigated predictors of sexual problems in two randomized controlled trials. Methods A subset of patients enrolled in TEXT and SOFT completed global and symptom-specific quality-of-life indicators, CES-Depression and MOS-Sexual Problems measures at baseline, six, 12 and 24 months. Mixed models tested the association of changes in treatment-induced symptoms (baseline to 6 months), depression at 6 months, and age at randomization with changes in sexual problems over 2 years. Results Sexual problems increased by 6 months and persisted at this level. Overall, patients with more severe worsening of vaginal dryness, sleep disturbances and bone or joint pain at 6 months reported a greater increase in sexual problems at all time-points. Depression scores were significantly associated with sexual problems in the short-term. All other symptoms had a smaller impact on sexual problems. Age was not associated with sexual problems at any time-point. Conclusion Among several key symptoms, vaginal dryness, sleep disturbance, and bone and joint pain significantly predicted sexual problems during the first 2 years. Early identification of these symptoms may contribute to timely and tailored interventions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available